Lilly Sees New Product Gains, But Older Drugs Still Limit Growth Potential
Lilly noted strong growth for new products, but gains seen in the fourth quarter included older products with limited potential going forward. That puts even more pressure on the R&D pipeline and the company's revised guidance, but executives were optimistic about future growth drivers.
You may also be interested in...
Trulicity, Taltz grew in the first quarter, but below analyst consensus estimates. Company points to price decreases as holding down growth.
Q1 Earnings Preview: From troubling safety data for tanezumab to pressure on insulin prices, Lilly is likely to face questions about controversies in its R&D pipeline and commercial portfolio during its first quarter earnings call on April 30.
GlaxoSmithKline will update investors on strategy after completing its Tesaro acquisition. Lilly may have guidance updates following its Loxo acquisition and Lartruvo setback news. Sanofi investors await a pair of new approvals, and AstraZeneca faces investors for the first time since the departure of Chief Medical Officer Sean Bohen and establishing a new organizational structure.